Kosin Med J.  2022 Dec;37(4):264-270. 10.7180/kmj.22.142.

Safety issues regarding melatonin use in child and adolescent patients with sleep problems

• Moon E
• Lee JH

• KMID: 2538856
• DOI: http://doi.org/10.7180/kmj.22.142

Abstract

Several studies have reported that melatonin may be effective in treating sleep problems in children and adolescents. However, evidence regarding the safety of melatonin use in children and adolescents in their growth and developmental stages is warranted. Therefore, we aimed to summarize the literature on the safety of melatonin use in children and adolescents with insomnia and sleep disturbances. According to existing evidence, there are no serious adverse effects of long-term melatonin use in children and adolescents. The common adverse effects reported in long-term studies are fatigue, somnolence, and mood swings. In addition, there is no evidence that long-term use of melatonin inhibits the natural secretion of melatonin. It is necessary to monitor potential drug interactions with medications such as inhibitors and enhancers of cytochrome P450 1A2 (CYP1A2). Furthermore, low CYP1A2 expression in young children requires proper dose adjustment. Although sufficient experience of melatonin use in children and adolescents has yet to be attained, accumulating evidence suggests that the use of melatonin in children and adolescents with sleep problems might be effective and tolerable. Considering the abuse or overdose risk of hypnotics or benzodiazepines, melatonin supplements may be a good therapeutic alternative. Future studies on the long-term safety of melatonin for physiological and mental function in children and adolescents are required to establish certainty about melatonin use in children and adolescents.

Keyword

Melatonin; Treatment; Child; Adolescent; Insomnia; Sleep

Reference

References

1. Johnson EO, Roth T, Schultz L, Breslau N. Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics. 2006; 117:e247–56.

2. Roberts RE, Roberts CR, Duong HT. Chronic insomnia and its negative consequences for health and functioning of adolescents: a 12-month prospective study. J Adolesc Health. 2008; 42:294–302.

3. Carmassi C, Palagini L, Caruso D, Masci I, Nobili L, Vita A, et al. Systematic review of sleep disturbances and circadian sleep desynchronization in autism spectrum disorder: toward an integrative model of a self-reinforcing loop. Front Psychiatry. 2019; 10:366.

4. Rzepka-Migut B, Paprocka J. Efficacy and safety of melatonin treatment in children with autism spectrum disorder and attention-deficit/hyperactivity disorder: a review of the literature. Brain Sci. 2020; 10:219.

5. Martinez-Cayuelas E, Rodriguez-Morilla B, Soriano-Guillen L, Merino-Andreu M, Moreno-Vinues B, Gavela-Perez T. Sleep problems and circadian functioning in children and adolescents with autism spectrum disorder. Pediatr Neurol. 2022; 126:57–64.

6. Bondopadhyay U, Diaz-Orueta U, Coogan AN. A systematic review of sleep and circadian rhythms in children with attention deficit hyperactivity disorder. J Atten Disord. 2022; 26:149–224.

7. Martinez-Cayuelas E, Moreno-Vinues B, Pozo RL, Rodrigo-Moreno M, Soto-Insuga V, Perez-Villena A. Sleep, chronotype, and behavior in adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr. 2022; 29:277–80.

8. Walters AS, Silvestri R, Zucconi M, Chandrashekariah R, Konofal E. Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders. J Clin Sleep Med. 2008; 4:591–600.

9. Lee JH, Moon E. Changes caused by the melatonergic system in young patients with mood disorders: a literature review. Moon Emot. 2021; 19:1–10.

10. de Zambotti M, Goldstone A, Colrain IM, Baker FC. Insomnia disorder in adolescence: diagnosis, impact, and treatment. Sleep Med Rev. 2018; 39:12–24.

11. Friedrich JM, Sun C, Geng X, Calello DP, Gillam M, Medeiros KL, et al. Child and adolescent benzodiazepine exposure and overdose in the United States: 16 years of poison center data. Clin Toxicol (Phila). 2020; 58:725–31.

12. Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr. 1996; 128(5 Pt 2):S32–7.

13. Brandenberger G, Gronfier C, Chapotot F, Simon C, Piquard F. Effect of sleep deprivation on overall 24 h growth-hormone secretion. Lancet. 2000; 356:1408.

14. Hagenauer MH, Perryman JI, Lee TM, Carskadon MA. Adolescent changes in the homeostatic and circadian regulation of sleep. Dev Neurosci. 2009; 31:276–84.

15. Crowley SJ, Wolfson AR, Tarokh L, Carskadon MA. An update on adolescent sleep: new evidence informing the perfect storm model. J Adolesc. 2018; 67:55–65.

16. Ma ZR, Shi LJ, Deng MH. Efficacy of cognitive behavioral therapy in children and adolescents with insomnia: a systematic review and meta-analysis. Braz J Med Biol Res. 2018; 51:e7070.

17. Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry. 2006; 45:512–9.

18. Halder S, Mahato AK. Cognitive behavior therapy for children and adolescents: challenges and gaps in practice. Indian J Psychol Med. 2019; 41:279–83.

19. Boafo A, Greenham S, Sullivan M, Bazaid K, Suntharalingam S, Silbernagel L, et al. Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists. Child Adolesc Psychiatry Ment Health. 2020; 14:10.

20. Badin E, Haddad C, Shatkin JP. Insomnia: the sleeping giant of pediatric public health. Curr Psychiatry Rep. 2016; 18:47.

21. Moon E, Partonen T, Beaulieu S, Linnaranta O. Melatonergic agents influence the sleep-wake and circadian rhythms in healthy and psychiatric participants: a systematic review and meta-analysis of randomized controlled trials. Neuropsychopharmacology. 2022; 47:1523–36.

22. Moon E, Kim K, Partonen T, Linnaranta O. Role of melatonin in the management of sleep and circadian disorders in the context of psychiatric illness. Curr Psychiatry Rep. 2022; 24:623–34.

23. Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017; 13:275–81.

24. Li J, Somers VK, Xu H, Lopez-Jimenez F, Covassin N. Trends in use of melatonin supplements among US adults, 1999-2018. JAMA. 2022; 327:483–5.

25. Huysmans S, De Hert M, Desplenter F. Melatonin and sleep disorders: overview of literature and testing in psychiatric practice. Tijdschr Psychiatr. 2019; 61:854–61.

26. Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018; 103:1155–62.

27. Parvataneni T, Srinivas S, Shah K, Patel RS. Perspective on melatonin use for sleep problems in autism and attention-deficit hyperactivity disorder: a systematic review of randomized clinical trials. Cureus. 2020; 12:e8335.

28. Palm L, Blennow G, Wetterberg L. Long-term melatonin treatment in blind children and young adults with circadian sleep-wake disturbances. Dev Med Child Neurol. 1997; 39:319–25.

29. Carr R, Wasdell MB, Hamilton D, Weiss MD, Freeman RD, Tai J, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007; 43:351–9.

30. Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res. 2009; 47:1–7.

31. Yuge K, Nagamitsu S, Ishikawa Y, Hamada I, Takahashi H, Sugioka H, et al. Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. BMC Psychiatry. 2020; 20:445.

32. Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018; 28:699–710.

33. Malow BA, Findling RL, Schroder CM, Maras A, Breddy J, Nir T, et al. Sleep, growth, and puberty after 2 years of prolonged-release melatonin in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2021; 60:252–61.

34. Matsumoto M, Sack RL, Blood ML, Lewy AJ. The amplitude of endogenous melatonin production is not affected by melatonin treatment in humans. J Pineal Res. 1997; 22:42–4.

35. Zisapel N. Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder. Expert Rev Clin Pharmacol. 2022; 15:175–85.

36. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011; 3:53–72.

37. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem. 1998; 251:893–8.

38. Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab. 1992; 75:367–9.

39. Sivan Y, Laudon M, Kuint J, Zisapel N. Low melatonin production in infants with a life-threatening event. Dev Med Child Neurol. 2000; 42:487–91.

40. Tauman R, Zisapel N, Laudon M, Nehama H, Sivan Y. Melatonin production in infants. Pediatr Neurol. 2002; 26:379–82.

41. Gitto E, Aversa S, Reiter RJ, Barberi I, Pellegrino S. Update on the use of melatonin in pediatrics. J Pineal Res. 2011; 50:21–8.

42. Fulia F, Gitto E, Cuzzocrea S, Reiter RJ, Dugo L, Gitto P, et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001; 31:343–9.

43. Hamrick SE, Ferriero DM. The injury response in the term newborn brain: can we neuroprotect? Curr Opin Neurol. 2003; 16:147–54.

44. Esposito S, Laino D, D'Alonzo R, Mencarelli A, Di Genova L, Fattorusso A, et al. Pediatric sleep disturbances and treatment with melatonin. J Transl Med. 2019; 17:77.

45. Baron KG, Reid KJ. Circadian misalignment and health. Int Rev Psychiatry. 2014; 26:139–54.

46. Chellappa SL, Morris CJ, Scheer FA. Circadian misalignment increases mood vulnerability in simulated shift work. Sci Rep. 2020; 10:18614.